前列腺癌主动监测中的mpMRI解读:PRECISE评分系统概述
本文综述了PRECISE评分系统在前列腺癌主动监测(AS)中应用mpMRI评估肿瘤进展的文献。PRECISE由欧洲肿瘤学院于2017年提出,用于序列mpMRI的放射学进展可能性评估,是目前唯一在多篇文献中评估的主要系统。综述讨论了其优势与潜在不足,指出PRECISE尚未成为mpMRI报告的标准。
要点
- PRECISE用于序列mpMRI评估前列腺癌AS中的放射学进展可能性。
- PRECISE是目前唯一在多篇文献中评估的AS影像进展评分系统。
- PRECISE尚未成为mpMRI报告的标准,需更多证据。
临床应用与阅片要点
- 在AS患者序列mpMRI报告中可参考PRECISE评分评估放射学进展可能性。
- 注意PRECISE尚未标准化,应结合临床和病理结果综合判断。
局限性
- PRECISE尚未成为mpMRI报告的标准。
- 序列mpMRI能否安全减少重复活检尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Active surveillance (AS) is now included in all major guidelines for patients with low-risk PCa and selected patients with intermediate-risk PCa. Several studies have highlighted the potential benefit of multiparametric magnetic resonance imaging (mpMRI) in AS and it has been adopted in some guidelines. However, uncertainty remains about whether serial mpMRI can help to safely reduce the number of required repeat biopsies under AS. In 2017, the European School of Oncology initiated the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) panel which proposed the PRECISE scoring system to assess the likelihood of radiological tumor progression on serial mpMRI. The PRECISE scoring system remains the only major system evaluated in multiple publications. In this review article, we discuss the current body of literature investigating the application of PRECISE as it is not as yet an established standard in mpMRI reporting. We delineate the strengths of PRECISE and its potential added value. Also, we underline potential weaknesses of the PRECISE scoring system, which might be tackled in future versions to further increase its value in AS.
引用
- Harder, Heming, Haider, et al. mpMRI Interpretation in Active Surveillance for Prostate Cancer-An overview of the PRECISE score. Abdom Radiol (NY). 2023. PMID: 37160473. doi:10.1007/s00261-023-03912-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。